Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
IPO Year: 2019
Exchange: NYSE
Website: alcon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Hold | Deutsche Bank | |
| 5/14/2025 | $102.00 → $99.00 | Buy | BTIG Research |
| 3/28/2025 | $107.00 → $110.00 | Buy | Needham |
| 3/25/2025 | Neutral → Buy | BofA Securities | |
| 1/24/2025 | $108.00 → $106.00 | Buy | Needham |
| 1/10/2025 | Neutral → Buy | Redburn Atlantic | |
| 12/17/2024 | $103.00 → $108.00 | Buy | Needham |
| 11/12/2024 | Buy | Needham | |
| 10/10/2024 | Sell → Neutral | Redburn Atlantic |
Fastest customizable press release news feed in the world
Believes STAAR's Sale Process Was Structured to Seal the Alcon Deal, Not to Maximize Value for Shareholders The Company Is Not Ripe for Sale at This Time Continues to Urge STAAR Shareholders to Vote "AGAINST" the Proposed Transaction Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to STAAR shareholders regarding the closing of STAAR's go-shop period and the revised offer of Alcon Inc. (SIX/NYSE:ALC) to acquire STAAR for $30.75 per share. The text of the letter is as follows: December 10
Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's Projections Have Not Changed Materially Continues to Urge STAAR Shareholders to Vote "AGAINST" the Proposed Transaction Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) by Alcon Inc. ("Alcon") (NYSE:ALC). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to oppose t
Agreement follows discussions with STAAR stockholders and the closure of STAAR's "go-shop" period New terms include an increase in acquisition price and reductions in payments to executives Alcon urges STAAR stockholders to vote in favor of the transaction in advance of the December 19, 2025, meeting Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an amended merger agreement for the acquisition of STAAR Surgical Company (NASDAQ:STAA, "STAAR")), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction. In November 2025, by mutual agree
Believes Belated Go-Shop Process Fails to Cure Fundamental Flaws in the Transaction's Process, Timing, and Price Expresses Disappointment that the Self-Interested and Conflicted Board Members Continue to Press Forward with a Transaction that Shareholders Have Already Roundly Rejected Continues to Urge STAAR Shareholders to Vote "AGAINST" the Proposed Transaction Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us," or "our") today issued the following open letter to the shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to oppose the proposed sale of the
Egan-Jones Takes No Comfort From Perfunctory Go-Shop Process and Says Concerns Regarding Objectivity and Fairness Remain the Same Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced that leading proxy advisory firm Egan-Jones Ratings Company ("Egan-Jones") has reaffirmed its recommendation that shareholders vote "AGAINST" the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) by Alcon Inc. ("Alcon") (NYSE:ALC) on the GREEN Proxy Card. Earlier today, the Company announced the completion of the belated, band-aid 30-day go-shop period and reiterated its support for the flawed transaction with Alcon despite the fact that
No Competing Acquisition Proposals Received Results of Go-Shop Process Validate the Effectiveness of the STAAR Board's Process Now is the Right Time to Sell the Business and Alcon is the Right Buyer STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR's amended merger agreement with Alcon Inc. (SIX/NYSE:ALC). The go-shop period expired at 11:59 p.m. Eastern Time on December 6, 2025. No proposals were received prior to the expiration. During the go-shop period, STAAR, with the assistance of its
Pursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process Broadwood Seeks to Remove the Directors Most Responsible for the Flawed Sale Process: Board Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the "Special Meeting") at STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to remove three directors from the Company's Board of Directors (the "Board"). Broadwood, which owns 30.2% of S
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder Alcon Waives All Matching Rights for Third-Party Proposals Alcon Waives Information Rights During the Go Shop Period Alcon to Engage with STAAR Stockholders to Solicit Support in Favor of the Merger Proposal STAAR Special Meeting of Stockholders Postponed to December 19, 2025 to Provide Time for Third-Party Proposals STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that
DFAN14A - ALCON INC (0001167379) (Filed by)
DFAN14A - ALCON INC (0001167379) (Filed by)
DEFM14A - ALCON INC (0001167379) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst downgraded Alcon from Overweight to Neutral
Deutsche Bank downgraded Alcon from Buy to Hold
BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously
BofA Securities upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $106.00 from $108.00 previously
Redburn Atlantic upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $108.00 from $103.00 previously
Needham reiterated coverage of Alcon with a rating of Buy
Redburn Atlantic upgraded Alcon from Sell to Neutral
Live Leadership Updates
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
This live feed shows all institutional transactions in real time.
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
Live finance-specific insights
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c
Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31
Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f
Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f
Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion's lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy candidate Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye d
Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as